MHRA Grants Marketing Authorization for LEO Pharma’s CHE Cream in Great Britain
The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorization in Great Britain for delgocitinib cream (Anzupgo, Leo Pharma) for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. Delgocitinib cream is now the first approved topical pan-Janus kinase (JAK) inhibitor […]